The observed risk reduction cannot be attributed to SGLT2i therapy alone but rather represents the cumulative effect of comprehensive diabetes and cardiovascular risk management, including the documented intensification of statin and ACE inhibitor/ARB therapy. This evidence concerns the gene ACE and diabetes mellitus.